Russell Investments Group Ltd. acquired a new stake in Voyager Therapeutics Inc (NASDAQ:VYGR) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 8,064 shares of the company’s stock, valued at approximately $139,000.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in VYGR. First Quadrant L P CA purchased a new position in Voyager Therapeutics in the second quarter valued at $86,000. Strs Ohio purchased a new position in Voyager Therapeutics in the second quarter valued at $574,000. Steward Partners Investment Advisory LLC purchased a new position in Voyager Therapeutics in the second quarter valued at $27,000. Bailard Inc. purchased a new position in Voyager Therapeutics in the second quarter valued at $1,116,000. Finally, Los Angeles Capital Management & Equity Research Inc. purchased a new position in Voyager Therapeutics in the second quarter valued at $345,000. 81.92% of the stock is owned by institutional investors.
A number of research analysts have weighed in on the stock. BidaskClub cut shares of Voyager Therapeutics from a “sell” rating to a “strong sell” rating in a report on Tuesday, August 27th. ValuEngine cut shares of Voyager Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, November 8th. Wedbush reaffirmed an “outperform” rating on shares of Voyager Therapeutics in a report on Wednesday, November 6th. Morgan Stanley cut their price objective on shares of Voyager Therapeutics from $28.00 to $26.00 and set an “equal weight” rating for the company in a report on Friday, October 11th. Finally, Nomura reaffirmed a “buy” rating and issued a $37.00 price objective on shares of Voyager Therapeutics in a report on Tuesday, August 13th. Two research analysts have rated the stock with a sell rating, four have given a hold rating and six have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $26.50.
VYGR stock opened at $14.30 on Thursday. The stock has a market capitalization of $530.84 million, a P/E ratio of -5.20 and a beta of 2.49. The firm has a 50-day simple moving average of $14.50 and a 200-day simple moving average of $19.77. Voyager Therapeutics Inc has a 52 week low of $7.76 and a 52 week high of $28.79.
Voyager Therapeutics (NASDAQ:VYGR) last released its earnings results on Wednesday, November 6th. The company reported ($0.41) EPS for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.42. The business had revenue of $20.43 million during the quarter, compared to analysts’ expectations of $3.94 million. Voyager Therapeutics had a negative net margin of 72.64% and a negative return on equity of 57.32%. On average, equities research analysts expect that Voyager Therapeutics Inc will post -1.6 earnings per share for the current year.
About Voyager Therapeutics
Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company’s lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson’s disease.
Featured Article: How can investors benefit from after-hours trading?
Want to see what other hedge funds are holding VYGR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Voyager Therapeutics Inc (NASDAQ:VYGR).
Receive News & Ratings for Voyager Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Voyager Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.
